Open calls · Research grant · Medicine
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
National Institutes of Health · Child Health and Human Development Extramural Research · PAR-25-266
Deadlines
- 16 Nov 2027 Deadline in 369 days
Who can apply
- Where the work is done
- United States
- Who applies
- An organisation
Money
- Per project
- up to $200k per project
- Total budget
- $200k
About the call
This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.
Text from the funder (US federal government, public domain).
Conditions in full
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
We sort calls into fields, career stages and countries automatically. Always check the conditions on the funder’s page before you apply.
Discussion
Applying too? Looking for partners? Ask here.